Figure 6.

CAR^LunX T Cells Suppress Growth of Lung Cancer Cells and Prolong Survival in a PDX Model in Mice

(A) Representative immunohistochemical-stained LunX-positive lung cancer tissue of patient number 1. Results are representative of three independent experiments. (B) Experimental protocol for the PDX-xenografted model used in (C)–(H). (C) Bodyweight of mice in (B) (n = 7 [CAR^LunX T cells], n = 7 [CAR^CD19 T cells], or n = 7 [PBS]) at various times (horizontal axis) after PDX tissue had been xenografted. (D) Tumor size in mice in (B) (n = 7 [CAR^LunX T cells], n = 7 [CAR^CD19 T cells], or n = 7 [PBS]) on days 3. (E) Tumor size in mice in (B) (n = 7 [CAR^LunX T cells], n = 7 [CAR^CD19 T cells], or n = 7 [PBS]) on day 12. (F) Tumor size in mice in (B) (n = 7 [CAR^LunX T cells], n = 7 [CAR^CD19 T cells], or n = 7 [PBS]) on day 15. (G) Survival of mice in (B) (n = 7 [CAR^LunX T cells], n = 7 [CAR^CD19 T cells], or n = 7 [PBS]) at various times (horizontal axis) after challenge. The survival rate was analyzed by log rank tests. (H) Representative immunofluorescence images using confocal microscopy of tumor-infiltrating CAR^LunX T cell- and CAR^CD19 T cell-treated LunX-positive PDX tumors. Partially infiltrating CAR-T cells were gated by the red frame. Scale bar, 50 μm. Each symbol (C and E–G) or line (D) represents an individual mouse. p values, one-way ANOVA followed by Tukey’s multiple-comparisons test (D–F).